The  ||| S:0 E:4 ||| DT
Food  ||| S:4 E:9 ||| NNP
and  ||| S:9 E:13 ||| CC
Drug  ||| S:13 E:18 ||| NNP
Administration  ||| S:18 E:33 ||| NNP
Amendments  ||| S:33 E:44 ||| NNP
Act  ||| S:44 E:48 ||| NNP
of  ||| S:48 E:51 ||| IN
2007 ||| S:51 E:55 ||| CD
:  ||| S:55 E:57 ||| :
drug  ||| S:57 E:62 ||| NN
safety  ||| S:62 E:69 ||| NN
and  ||| S:69 E:73 ||| CC
health-system  ||| S:73 E:87 ||| JJ
pharmacy  ||| S:87 E:96 ||| JJ
implications  ||| S:96 E:109 ||| NNS
To  ||| S:109 E:112 ||| TO
describe  ||| S:112 E:121 ||| VB
the  ||| S:121 E:125 ||| DT
drug  ||| S:125 E:130 ||| NN
safety  ||| S:130 E:137 ||| NN
provisions  ||| S:137 E:148 ||| NNS
of  ||| S:148 E:151 ||| IN
the  ||| S:151 E:155 ||| DT
Food  ||| S:155 E:160 ||| NNP
and  ||| S:160 E:164 ||| CC
Drug  ||| S:164 E:169 ||| NNP
Administration  ||| S:169 E:184 ||| NNP
Amendments  ||| S:184 E:195 ||| NNP
Act  ||| S:195 E:199 ||| NNP
( ||| S:199 E:200 ||| -LRB-
FDAAA ||| S:200 E:205 ||| NNP
)  ||| S:205 E:207 ||| -RRB-
of  ||| S:207 E:210 ||| IN
2007 ||| S:210 E:214 ||| CD
,  ||| S:214 E:216 ||| ,
including  ||| S:216 E:226 ||| VBG
risk  ||| S:226 E:231 ||| NN
evaluation  ||| S:231 E:242 ||| NN
and  ||| S:242 E:246 ||| CC
mitigation  ||| S:246 E:257 ||| JJ
strategies  ||| S:257 E:268 ||| NNS
( ||| S:268 E:269 ||| -LRB-
REMS ||| S:269 E:273 ||| NNP
) ||| S:273 E:274 ||| -RRB-
,  ||| S:274 E:276 ||| ,
and  ||| S:276 E:280 ||| CC
the  ||| S:280 E:284 ||| DT
implications  ||| S:284 E:297 ||| NNS
for  ||| S:297 E:301 ||| IN
health-system  ||| S:301 E:315 ||| JJ
pharmacists ||| S:315 E:326 ||| NNS
.  ||| S:326 E:328 ||| .
The  ||| S:328 E:332 ||| DT
FDAAA  ||| S:332 E:338 ||| NNP
grants  ||| S:338 E:345 ||| VBZ
FDA  ||| S:345 E:349 ||| NNP
new  ||| S:349 E:353 ||| JJ
authorities  ||| S:353 E:365 ||| NNS
to  ||| S:365 E:368 ||| TO
require  ||| S:368 E:376 ||| VB
postmarketing  ||| S:376 E:390 ||| JJ
studies  ||| S:390 E:398 ||| NNS
or  ||| S:398 E:401 ||| CC
clinical  ||| S:401 E:410 ||| JJ
trials  ||| S:410 E:417 ||| NNS
of  ||| S:417 E:420 ||| IN
human  ||| S:420 E:426 ||| JJ
drugs  ||| S:426 E:432 ||| NNS
and  ||| S:432 E:436 ||| CC
to  ||| S:436 E:439 ||| TO
require  ||| S:439 E:447 ||| VB
REMS ||| S:447 E:451 ||| NNP
.  ||| S:451 E:453 ||| .
The  ||| S:453 E:457 ||| DT
REMS  ||| S:457 E:462 ||| NNP
provisions  ||| S:462 E:473 ||| NNS
of  ||| S:473 E:476 ||| IN
the  ||| S:476 E:480 ||| DT
FDAAA  ||| S:480 E:486 ||| NNP
represent  ||| S:486 E:496 ||| VBP
the  ||| S:496 E:500 ||| DT
evolution  ||| S:500 E:510 ||| NN
of  ||| S:510 E:513 ||| IN
FDA  ||| S:513 E:517 ||| NNP
drug  ||| S:517 E:522 ||| NN
safety  ||| S:522 E:529 ||| NN
requirements ||| S:529 E:541 ||| NNS
.  ||| S:541 E:543 ||| .
Components  ||| S:543 E:554 ||| NNS
of  ||| S:554 E:557 ||| IN
REMS  ||| S:557 E:562 ||| NNP
include  ||| S:562 E:570 ||| VBP
medication  ||| S:570 E:581 ||| JJ
guides ||| S:581 E:587 ||| NNS
,  ||| S:587 E:589 ||| ,
patient  ||| S:589 E:597 ||| JJ
package  ||| S:597 E:605 ||| NN
inserts ||| S:605 E:612 ||| NNS
,  ||| S:612 E:614 ||| ,
and  ||| S:614 E:618 ||| CC
communication  ||| S:618 E:632 ||| NN
plans  ||| S:632 E:638 ||| NNS
for  ||| S:638 E:642 ||| IN
health  ||| S:642 E:649 ||| NN
care  ||| S:649 E:654 ||| NN
providers ||| S:654 E:663 ||| NNS
.  ||| S:663 E:665 ||| .
For  ||| S:665 E:669 ||| IN
medications  ||| S:669 E:681 ||| NN
with  ||| S:681 E:686 ||| IN
known  ||| S:686 E:692 ||| JJ
safety  ||| S:692 E:699 ||| NN
risks ||| S:699 E:704 ||| NNS
,  ||| S:704 E:706 ||| ,
the  ||| S:706 E:710 ||| DT
FDAAA  ||| S:710 E:716 ||| NNP
requires  ||| S:716 E:725 ||| VBZ
the  ||| S:725 E:729 ||| DT
inclusion  ||| S:729 E:739 ||| NN
in  ||| S:739 E:742 ||| IN
the  ||| S:742 E:746 ||| DT
REMS  ||| S:746 E:751 ||| NNP
process  ||| S:751 E:759 ||| NN
of  ||| S:759 E:762 ||| IN
elements  ||| S:762 E:771 ||| NNS
to  ||| S:771 E:774 ||| TO
ensure  ||| S:774 E:781 ||| VB
safe  ||| S:781 E:786 ||| JJ
use ||| S:786 E:789 ||| NN
.  ||| S:789 E:791 ||| .
These  ||| S:791 E:797 ||| DT
elements  ||| S:797 E:806 ||| NNS
may  ||| S:806 E:810 ||| MD
include  ||| S:810 E:818 ||| VB
special  ||| S:818 E:826 ||| JJ
training  ||| S:826 E:835 ||| NN
or  ||| S:835 E:838 ||| CC
certification  ||| S:838 E:852 ||| NN
for  ||| S:852 E:856 ||| IN
prescribing  ||| S:856 E:868 ||| NN
or  ||| S:868 E:871 ||| CC
dispensing ||| S:871 E:881 ||| NN
,  ||| S:881 E:883 ||| ,
dispensing  ||| S:883 E:894 ||| VBG
only  ||| S:894 E:899 ||| RB
under  ||| S:899 E:905 ||| IN
certain  ||| S:905 E:913 ||| JJ
circumstances ||| S:913 E:926 ||| NNS
,  ||| S:926 E:928 ||| ,
special  ||| S:928 E:936 ||| JJ
monitoring ||| S:936 E:946 ||| NN
,  ||| S:946 E:948 ||| ,
and  ||| S:948 E:952 ||| CC
the  ||| S:952 E:956 ||| DT
use  ||| S:956 E:960 ||| NN
of  ||| S:960 E:963 ||| IN
patient  ||| S:963 E:971 ||| JJ
registries ||| S:971 E:981 ||| NN
.  ||| S:981 E:983 ||| .
Standardization  ||| S:983 E:999 ||| NNP
of  ||| S:999 E:1002 ||| IN
elements  ||| S:1002 E:1011 ||| NNS
to  ||| S:1011 E:1014 ||| TO
ensure  ||| S:1014 E:1021 ||| VB
the  ||| S:1021 E:1025 ||| DT
safe  ||| S:1025 E:1030 ||| JJ
use  ||| S:1030 E:1034 ||| NN
of  ||| S:1034 E:1037 ||| IN
drugs  ||| S:1037 E:1043 ||| NNS
with  ||| S:1043 E:1048 ||| IN
known  ||| S:1048 E:1054 ||| VBN
serious  ||| S:1054 E:1062 ||| JJ
risks  ||| S:1062 E:1068 ||| NNS
is  ||| S:1068 E:1071 ||| VBZ
needed  ||| S:1071 E:1078 ||| VBN
so  ||| S:1078 E:1081 ||| RB
that  ||| S:1081 E:1086 ||| IN
REMS  ||| S:1086 E:1091 ||| NNP
are  ||| S:1091 E:1095 ||| VBP
not  ||| S:1095 E:1099 ||| RB
unduly  ||| S:1099 E:1106 ||| RB
burdensome  ||| S:1106 E:1117 ||| JJ
for  ||| S:1117 E:1121 ||| IN
the  ||| S:1121 E:1125 ||| DT
health  ||| S:1125 E:1132 ||| NN
care  ||| S:1132 E:1137 ||| NN
delivery  ||| S:1137 E:1146 ||| NN
system  ||| S:1146 E:1153 ||| NN
and  ||| S:1153 E:1157 ||| CC
do  ||| S:1157 E:1160 ||| VBP
not  ||| S:1160 E:1164 ||| RB
needlessly  ||| S:1164 E:1175 ||| RB
limit  ||| S:1175 E:1181 ||| VB
patient  ||| S:1181 E:1189 ||| JJ
access  ||| S:1189 E:1196 ||| NN
to  ||| S:1196 E:1199 ||| TO
the  ||| S:1199 E:1203 ||| DT
drugs ||| S:1203 E:1208 ||| NNS
.  ||| S:1208 E:1210 ||| .
